[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"residual-neuromuscular-block\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:residual-neuromuscular-block":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616729","impact-of-sugammadex-versus-neostigmine-on-early-postoperative-pulmonary-function-100616729",false,"NCT07309393","Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function","Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial","Inclusion Criteria:\n\n* Scheduled for elective unilateral thoracoscopic partial lung resection, with expected resection not exceeding one lung segment.\n* Age between 18 and 80 years.\n* American Society of Anesthesiologists (ASA) Physical Status classification I-III.\n\nExclusion Criteria:\n\n* Contraindications to drug use, such as history of allergy, epilepsy, angina, ventricular tachycardia; contraindicated in patients with mechanical intestinal obstruction or urinary tract obstruction; contraindicated in cases of arrhythmia, bradycardia (\\\u003C50 beats per minute), hypotension, or increased vagal tone; contraindicated in patients currently using depolarizing muscle relaxants (e.g., succinylcholine).\n* Inability to correctly cooperate with portable lung function testing.\n* Hepatic or renal insufficiency.\n* Pregnancy, lactation, potential for pregnancy, or planning pregnancy.\n* Preoperative history of drug abuse or addiction.\n* Second surgery during postoperative hospitalization.\n* Patients who refuse to participate.\n* Other situations deemed inappropriate by the investigators shall be accompanied by a statement of the reasons.","ALL","18 Years","80 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"NA","Residual neuromuscular blockade (NMB) after general anesthesia increases the risk of postoperative respiratory complications (atelectasis, pneumonia, re-intubation) and delays pulmonary function recovery. Sugammadex, a γ-cyclodextrin that directly encapsulates rocuronium, reverses NMB rapidly and completely without cholinergic side effects, whereas neostigmine requires co-administration of an antimuscarinic and may leave residual blockade. In this multicenter, randomized, double-blind, controlled trial, 240 adult patients (ASA I-III) undergoing elective thoracoscopic lung resection (≤ 1 segment) will be randomized 1:1 to receive sugammadex (2 mg\u002Fkg) or neostigmine (0.03 mg\u002Fkg) + atropine (0.015 mg\u002Fkg) at the end of surgery. The primary endpoint is the percent decline in forced expiratory volume in 1 second (FEV₁) at 1 hour post-extubation compared to preoperative baseline; a ≥ 5% improvement with sugammadex is hypothesized. Secondary endpoints include FEV₁ at days 1-3, pain scores, opioid consumption, gastrointestinal recovery, quality of recovery (QoR-15), neuromuscular monitoring (TOF ratio), and incidence of postoperative pulmonary and surgical complications.",[27],"Residual Neuromuscular Block",[29,30,31,32,33],"Sugammadex","Neostigmine","Forced Expiratory Volume (FEV1)","Lung Resection","Quality of Recovery","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-22","ACTUAL",{"date":40,"type":38},"2025-12-30",{"date":42,"type":21},"2026-09-30",{"name":44,"class":45},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",3,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100596341","phase-4-reversal-of-pipecuronium-induced-neuromuscular-blockade-with-sugammadex-during-sevoflurane-anesthesia-100596341","NCT07044193","Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia","Reversal of Pipecuronium-induced Neuromuscular Blockade With Sugammadex During Sevoflurane Anesthesia: a Drug Safety Randomised Controlled Trial","RPINMBWS","Inclusion Criteria:\n\n* 80 adult general surgery and neurosurgical patients are enrolled in the study after giving an informed written consent regarding their participation.\n* Age: between 18-65 years;\n* ASA score: 1-3;\n* BMI 18.5-25 (normal body weight);\n* Males and females were recruited in an equal ratio;\n* Minimal surgical time of at least ≥ 40 minutes;\n* Procedures requiring endotracheal intubation;\n\nExclusion Criteria:\n\n* Diseases affecting neuromuscular function (myopathies, severe liver and kidney failure);\n\n  * Drugs affecting neuromuscular function (magnesium, aminoglycosides);\n  * Difficult airway, or anticipated difficult intubation;\n  * Pregnancy (a pregnancy test is performed in women of childbearing age to rule out pregnancy);\n  * Breast-feeding;\n  * Acute surgery;\n  * COPD\n  * Glaucoma\n  * History of previous allergic\u002Fanaphylactic reactions","65 Years",{"count":57,"type":21},80,[59],"PHASE4","Safety during modern practice of anaesthesia is of great concern. Patients admitted daily for surgical procedures undergoing general anaesthesia for different types of operations are exposed to different risks, starting from the anaesthesia and ending with the surgical intervention. Aim of the study is to provide a comprehensive and evidence based data regarding the safety of the neuromuscular blocking agents used in modern anaesthesia practice, precisely Rocuronium and Pipecuronium, as well as the reversal agents such as Sugammadex, which is the sole agent in use in practice nowadays. A routine anaesthetic practice will be performed during the whole period of our study after strict patient selection criteria. Intraoperative standard monitoring as per local and international guidelines will be applied, this includes Spo2, ECG, NIBP\u002FIBP, etCO2, BIS and Tetragaph for neuromuscular blockade monitoring. After induction of anaesthesia and prior to the administration of the muscle relaxant agent, a TOFC (Train of Four Count) will be registered as the starting point. Throughout the anaesthetic time, there will be continuous TOF monitoring. The anaesthesia will be maintained by sevoflurane. Also, the recruited samples will be divided according to the neuromuscular blockade agents administered, either Rocuronium or Pipecuronium. At the end of the surgical procedure, the time lapse between the administration of the reversal agent Sugammadex and a TOF ratio of 0.9 is registered as our primary end point. TOF measures will be performed in the postoperative period, to make sure there is no residual neuromuscular blockade in the early postoperative phase. The study will not only monitor the safety of the neuromuscular blocking agents in use, but will also monitor any signs of anaphylaxis due to their administration both intra and postoperatively.",[62,27,63],"Neuromuscular Blocking Agents","Reversal of Neuromuscular Blockade",[65],"reversal of neuromuscular blockade","NOT_YET_RECRUITING","2025-06-27",{"date":69,"type":38},"2025-06-29",{"date":71,"type":21},"2025-06-26",{"date":73,"type":21},"2028-12-31",{"name":75,"class":45},"Tamas Vegh, MD",1]